drugset / Trial / NCT02697292
IVIG in Patients With VGKC Ab Associated Autoimmune Epilepsy
Phase 3
Terminated
17 enrolled
Mayo Clinic
Grifols Shared Services North America, Inc. · collabOption Care · collab
RandomizedParallel-groupQuadruple-blindTreatment
Summary
The purpose of this study is to determine whether intravenous immunoglobulin (IVIG) treatment reduces significantly the number of epileptic seizures in cases of autoimmune epileptic seizures.
Timeline
- Start
- 2016-02
- Primary completion
- 2018-12-03
- Completion
- 2018-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | 0.6 g/kg | Intravenous |